Business Wire

Gilead Sciences Appoints Merdad Parsey, MD, PhD as Chief Medical Officer

Share

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that Merdad Parsey, MD, PhD, will join the company as Chief Medical Officer, effective November 1. Dr. Parsey will be responsible for the company’s global clinical development and medical affairs organizations. He will join the company’s senior leadership team and will report directly to Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. Under a new structure, William Lee, PhD, Gilead’s Executive Vice President, Research will separately report to Mr. O’Day.

Dr. Parsey joins Gilead from Genentech, Inc., a member of the Roche Group, where he currently holds the position of Senior Vice President, Early Clinical Development in the Genentech Research and Early Development (gRED) group. In this role, he leads clinical development, quality, compliance, informatics and clinical operations functions. He brings to Gilead significant clinical expertise across a broad array of therapeutic areas, including inflammation, oncology and infectious diseases.

“I am delighted to welcome Merdad, a seasoned and highly respected scientist, clinician and leader, to Gilead,” said Mr. O’Day. “Throughout his career, he has built a reputation as an outstanding leader among academic, industry and medical communities alike. I know Merdad’s exceptional skills and expertise will be of great benefit to Gilead as we focus on rapidly expanding our pipeline and clinical development portfolio through internal efforts and external partnerships.”

Prior to his most recent tenure with Genentech, Dr. Parsey served as President and CEO of 3-V Biosciences. He has also held development roles at Sepracor, Regeneron and Merck, Inc. and has served as Assistant Professor of Medicine and Director of Critical Care Medicine at New York University School of Medicine. Dr. Parsey completed his MD and PhD at the University of Maryland, Baltimore, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.

“I have had many opportunities over the course of my career to help shape clinical development strategies and programs, and I am profoundly excited to bring those experiences to Gilead, an organization I have long admired,” said Dr. Parsey. “I am looking forward to working with the company’s talented teams to advance clinical development programs and build a robust pipeline that has the opportunity to change the trajectory of disease and transform the care of many more people in need around the world.”

About Gilead Sciences

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contact information

Sung Lee, Investors
(650) 524-7792

Marni Kottle, Media
(650) 522-5388

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Isturisa® Is Now Available as a Medical Treatment for Cushing's Syndrome in Germany16.7.2020 18:00:00 EESTPress release

Cortisol synthesis inhibitor osilodrostat (Isturisa®) is now available in Germany as of July 15, 2020, as a promising new therapy option for medical treatment of adult patients with endogenous Cushing’s syndrome (CS).1,4 Isturisa® was approved by the European Commission on January 9, 2020. The approval of Isturisa® (osilodrostat) is based on the results of the pivotal phase III study, LINC-3, in which the efficacy and safety of osilodrostat in 137 patients with Cushing’s disease were assessed. A significantly higher proportion of patients with Cushing’s disease treated with Isturisa® maintained normal mean urinary free cortisol (mUFC) at the end of the 8‐week randomized withdrawal period (week 34) versus placebo (86% vs 29%). Cortisol level control is the primary objective in the treatment of patients with Cushing’s disease. Thus, the study successfully met its primary and key secondary endpoint.1,3 Moreover, the results showed that osilodrostat resulted in a rapid and sustained reduct

PMI Launches “Our World Is Not an Ashtray” Initiative and Aims to Halve Plastic Litter from Products by 202516.7.2020 17:13:00 EESTPress release

Philip Morris International Inc. (PMI) (NYSE:PM) today launched “Our World Is Not an Ashtray,” a new global initiative to raise awareness and drive a long-term change in behavior and attitudes around cigarette butt littering. The initiative supports PMI’s litter reduction target—described in its Integrated Report 2019—to achieve a 50 percent reduction of the plastic litter from its products by 2025 (vs. 2021 baseline). The initiative, launched on WorldNoAshtray.com, aims to educate the public about the environmental impact of cigarette butt littering and inspire adult smokers to change littering habits. “We seek to make cigarette butt littering socially unacceptable,” said Huub Savelkouls, Chief Sustainability Officer at PMI. “‘Our World Is Not an Ashtray’ is an important initiative in our multipronged approach to addressing this important issue.” To track progress against its goal, PMI is working with three organizations—Litterati, Cortexia, and CARTO—to implement a data-driven approa

European Industry Leaders From Energy, Mobility & Sustainability Join Energy Impact Partners Global Innovation Platform16.7.2020 17:00:00 EESTPress release

Energy Impact Partners (EIP), the global investment platform leading the transition to a sustainable energy future, has announced the formation of a European Coalition to advance new technologies and tackle climate change. EIP works closely with its investors -- more than 25 of the largest, most innovative, and environmentally conscious energy and industrial companies as well as climate-investors -- to develop cutting-edge solutions across four continents through a unique collaborative model. The EIP network collaborates by sharing insights, investing in innovative and transformative businesses, and then amplifying entrepreneurs' growth through dedicated partnerships. “Our proven model is based on collaboration, learning, and sharing -- and it can only thrive with the right partners. We are thrilled to see some of the most innovative European players and AGL, the leading utility in Australia, join our mission as founding members.” - Matthias Dill, CEO & Managing Director Europe for Ene

Andersen Global Continues Caribbean Expansion with Additional Presence in Trinidad and Tobago16.7.2020 16:30:00 EESTPress release

Andersen Global announces an expanded presence in Trinidad and Tobago with collaborating firm, Johnson, Camacho & Singh, adding depth to the organization’s platform as it accelerates its expansion efforts the Caribbean region. Located in Port of Spain, Trinidad, the full-service law firm, is well known throughout the region, with thirteen attorneys covering corporate and commercial law, commercial litigation, property development and conveyancing, oil and gas, mergers and acquisitions, insolvency, and banking and finance. Additionally, the firm is ranked Band 2 for General Business Law in Trinidad and Tobago, Global Ranking by Chambers & Partners. The partners of Johnson, Camacho & Singh are of the view that the collaboration with Andersen Global is the next milestone for the firm as it will allow us to extend beyond the regional market and provide our clients with the resources of a global firm. Senior Partner, Stephen Singh, added, “Expertise and professionalism are important qualiti

Survey: More Than Half of Sustainability Leaders Believe That Consumer Demand for Environmental Action Has Grown During COVID-19, and Many Think They May Lose Customers If They Don’t Meet Commitments16.7.2020 16:05:00 EESTPress release

A recent global survey shows 54 percent of sustainability leaders at apparel and textile brands say they’ve seen their customers’ demands for environmentally sustainable practices and products increase since the beginning of the COVID-19 pandemic, but 59 percent said they believe customers will still continue to prioritize price when making purchases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200716005189/en/ Simplified Infographic Covid-19-Survey Highlights (Graphic: Business Wire) The U.S. Cotton Trust Protocol conducted this survey to find how sustainability programs at brands and retailers had changed in a post-COVID world. The survey found that 43% of respondents believe COVID-19 has had a positive impact on investments in sustainability efforts during this period, while 40% believe it has had a negative impact. Likewise, they believe their customers are facing the same struggle between their pocketbooks and the en

USB-IF Publishes USB Device Class Specification for MIDI Devices v2.016.7.2020 16:00:00 EESTPress release

USB Implementers Forum (USB-IF), the support organization for the advancement and adoption of USB technology, today announced an updated USB Device Class Definition for MIDI Devices, Version 2.0 in support of MIDI 2.0 devices. The standard represents an industry-wide effort by the USB-IF, MIDI Manufacturers Association (MMA), and Association of Musical Electronics Industry (AMEI) to provide MIDI users with an expanded MIDI environment connected by USB. “USB-IF is proud to support the MMA and AMEI by publishing an updated USB Device Class Specification for next-generation MIDI devices,” said Jeff Ravencraft, USB-IF President and COO. “USB has been an integral part of the MIDI environment over the past 20 years, and we look forward to seeing innovative new devices that are enabled by this updated specification.” Mike Kent, Project Chair of the USB MIDI class specification and Chairman of the MMA's MIDI 2.0 Working Group, said, "This updated specification delivers many improvements that m

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom